<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04228991</url>
  </required_header>
  <id_info>
    <org_study_id>OCOG-2019-RHEAL</org_study_id>
    <nct_id>NCT04228991</nct_id>
  </id_info>
  <brief_title>Hypofractionated LocoRegional Radiotherapy in Breast Cancer</brief_title>
  <acronym>RHEAL</acronym>
  <official_title>Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema (RHEAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ontario Clinical Oncology Group (OCOG)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ontario Clinical Oncology Group (OCOG)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine if hypofractionated radiotherapy (RT) delivered over 1&#xD;
      week to the breast and regional nodes (supraclavicular, axillary and internal mammary)&#xD;
      following breast conserving surgery (BCS), or to the chest wall and regional nodes following&#xD;
      mastectomy, is non-inferior to conventional fractionation delivered over 3 weeks in patients&#xD;
      with node positive breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-centre, randomized, non-inferior, phase III study comparing two radiation treatment&#xD;
      modalities, conventional fractionation with hypofractionation for locoregional RT. Eligible,&#xD;
      consenting patients with newly diagnosed and histologically confirmed invasive carcinoma of&#xD;
      the breast without evidence of metastatic disease; treated with definitive surgery [BCS or&#xD;
      mastectomy with nodal staging using sentinel lymph node biopsy (SLNB) or axillary lymph node&#xD;
      dissection (ALND)] will be randomized in a 1:1 fashion to either conventional locoregional RT&#xD;
      (control group) or hypofractionated locoregional RT (experimental group). Stratification&#xD;
      factors include: body mass index, the performance of ALND, type of surgery (BCS or&#xD;
      mastectomy) and clinical centre.&#xD;
&#xD;
      Study participants will be assessed for lymphedema, the primary outcome, by measuring arm&#xD;
      volume. Arm mobility will be assessed by measuring arm movement. Study participants will be&#xD;
      assessed for acute and late radiation toxicities, during and post RT. Study participants will&#xD;
      be followed and assessed annually for breast cancer recurrence (BCR), new second cancers,&#xD;
      quality of life (QOL) and overall survival. Cost effectiveness and cost utility will also be&#xD;
      determined. The planned sample size is 588 study participants. The study will be conducted at&#xD;
      clinical centres throughout Canada.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphedema</measure>
    <time_frame>3 years post randomization</time_frame>
    <description>Lymphedema defined as relative volume change (RVC) &gt;10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast cancer recurrence</measure>
    <time_frame>Annually for 5 years post randomization</time_frame>
    <description>Both locoregional and distant recurrence and second cancers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Annually for 5 years post randomization</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation toxicity</measure>
    <time_frame>During last week of radiotherapy, at 3 months post radiotherapy and annually for 5 years post randomization</time_frame>
    <description>Acute and late radiation toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm mobility</measure>
    <time_frame>1 and 3 years post randomization</time_frame>
    <description>Assessed by measuring the straight lateral abduction of both the ipsilateral and contralateral arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life with respect to daily health and activities</measure>
    <time_frame>During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization</time_frame>
    <description>Impact on quality of life will be assessed with the European Organization for Research in Treatment of Cancer and the Breast Cancer Specific Module 23. The scale is 1 to 4 where a higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perception of lymphedema</measure>
    <time_frame>During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization</time_frame>
    <description>Impact of lymphedema on quality of life will be assessed with the National Surgical Adjuvant Breast and Bowel Project questionnaire. The scale is 1 to 5 where a higher score means a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perception of breast cosmesis</measure>
    <time_frame>1 and 3 years post randomization</time_frame>
    <description>Patient-reported breast cosmesis using a Breast Cosmesis Questionnaire to study the late effects of radiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Resource Utilization</measure>
    <time_frame>During radiotherapy, at 3 months post radiotherapy and annually for 5 years post randomization</time_frame>
    <description>Health Care Resource Utilization will be estimated using dates and duration of radiotherapy treatment and emergency department visits and hospitalizations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Costs</measure>
    <time_frame>During last week of radiotherapy, at 3 months post radiotherapy and 1 and 3 years post randomization</time_frame>
    <description>Patient costs will be assessed using a Time Off Work Questionnaire to study the financial impact of breast cancer and its treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">588</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Radiotherapy</condition>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional fractionation for locoregional radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypofractionation for locoregional radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Locoregional radiation treatment - Conventional fractionation</intervention_name>
    <description>40 Gray in 15 daily fractions over 3 weeks</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Locoregional radiation treatment - Hypofractionation</intervention_name>
    <description>26 Gray in 5 daily fractions over 1 week</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed invasive carcinoma of the breast.&#xD;
&#xD;
          2. Treated with definitive surgery (BCS or mastectomy with nodal staging using SLNB or&#xD;
             ALND) with clear margins of excision.*&#xD;
&#xD;
             Note: *Patients with limited positive posterior margin where disease is resected to&#xD;
             chest wall or limited positive anterior margin where disease is resected to dermis are&#xD;
             eligible.&#xD;
&#xD;
          3. Breast cancer stage after definitive surgery.&#xD;
&#xD;
               -  if neoadjuvant chemotherapy was not administered: pathologic stage T1-3, N1-2&#xD;
&#xD;
               -  if neoadjuvant chemotherapy was administered: clinical stage T1-3, N1-2&#xD;
                  (histologically node positive) and pathologic stage T0-3, N0-2†&#xD;
&#xD;
             Note: †Patients who are histologically node positive prior to chemotherapy and who&#xD;
             have complete response in the lymph nodes are eligible.&#xD;
&#xD;
          4. No evidence of metastatic disease.&#xD;
&#xD;
          5. Candidate for locoregional radiotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years.&#xD;
&#xD;
          2. Clinical stages T4 and/or N3.&#xD;
&#xD;
          3. Clinical lymphedema in the ipsilateral arm or breast/chest wall.&#xD;
&#xD;
          4. Presence of known medical conditions that would preclude follow-up for 5 years.&#xD;
&#xD;
          5. Synchronous or previous contralateral breast cancer.&#xD;
&#xD;
          6. Breast reconstruction.&#xD;
&#xD;
          7. History of non-breast malignancy within the last 5 years other than non-melanoma skin&#xD;
             cancer or treated in-situ carcinoma.&#xD;
&#xD;
          8. Previous radiotherapy to the ipsilateral breast or chest wall or serious non-malignant&#xD;
             disease e.g. scleroderma, severe lung or heart disease that would preclude&#xD;
             radiotherapy.&#xD;
&#xD;
          9. Known pregnancy or currently lactating.&#xD;
&#xD;
         10. Geographic inaccessibility for follow-up.&#xD;
&#xD;
         11. Inability to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Whelan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Juravinski Cancer Centre, McMaster University, Hamilton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucy Spadafora</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42655</phone_ext>
    <email>spadafl@mcmaster.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Nason</last_name>
    <phone>905-527-2299</phone>
    <phone_ext>42622</phone_ext>
    <email>nasons@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry Qian</last_name>
    </contact>
    <investigator>
      <last_name>Jeff Cao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Downey</last_name>
    </contact>
    <investigator>
      <last_name>Jocelyn Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer - Vancouver Island Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily White</last_name>
    </contact>
    <investigator>
      <last_name>Tanya Berrang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mira Goldberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre - UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E0</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicky Gillman</last_name>
    </contact>
    <investigator>
      <last_name>Kathy Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu de Lévis (CISSS CA)</name>
      <address>
        <city>Lévis</city>
        <state>Quebec</state>
        <zip>G6V 3Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bedard</last_name>
    </contact>
    <investigator>
      <last_name>Anne Dagnault</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre-Cedars Cancer Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Perna</last_name>
    </contact>
    <investigator>
      <last_name>Tarek Hijal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM - Centre Hospitalier de L'Universite de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Rousseau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU-de Québec-Université de Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Allard</last_name>
    </contact>
    <investigator>
      <last_name>Valerie Theberge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sherbrooke University Hospital Centre</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Couture</last_name>
    </contact>
    <investigator>
      <last_name>Sawyna Provencher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypofractionated</keyword>
  <keyword>Locoregional</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Lymphedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

